Literature DB >> 29311386

Dendritic Cell-Based Cancer Vaccines.

Patricia M Santos1, Lisa H Butterfield2,3,4,5,6.   

Abstract

Dendritic cells (DC) are specialized immune cells that play a critical role in promoting an immune response against Ags, which can include foreign pathogenic Ags and self-tumor Ags. DC are capable of boosting a memory T cell response but most importantly they are effective initiators of naive T cell responses. Many years of studies have focused on the use of DC vaccines against cancer to initiate and shape an antitumor-specific immune response and/or boost existing spontaneous antitumor T cell responses. In this study we give a brief overview of DC biology, function, and cellular subsets, and review the current status of the field of DC as cancer vaccines.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29311386      PMCID: PMC5880540          DOI: 10.4049/jimmunol.1701024

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  104 in total

Review 1.  C-type lectin receptors on dendritic cells and Langerhans cells.

Authors:  Carl G Figdor; Yvette van Kooyk; Gosse J Adema
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

Review 2.  Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens.

Authors:  William R Heath; Gabrielle T Belz; Georg M N Behrens; Christopher M Smith; Simon P Forehan; Ian A Parish; Gayle M Davey; Nicholas S Wilson; Francis R Carbone; Jose A Villadangos
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

Review 3.  Cutaneous dendritic cells.

Authors:  Jenny Valladeau; Sem Saeland
Journal:  Semin Immunol       Date:  2005-08       Impact factor: 11.130

4.  Tumor Microenvironment: No Effector T Cells without Dendritic Cells.

Authors:  Christina Pfirschke; Marie Siwicki; Hsin-Wei Liao; Mikael J Pittet
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

Review 5.  Tolerogenic dendritic cells and their role in transplantation.

Authors:  Mohamed Ezzelarab; Angus W Thomson
Journal:  Semin Immunol       Date:  2011-07-07       Impact factor: 11.130

6.  A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer.

Authors:  Rebecca L Prue; Frank Vari; Kristen J Radford; Hui Tong; Melinda Y Hardy; Rachael D'Rozario; Nigel J Waterhouse; Tony Rossetti; Robert Coleman; Christopher Tracey; Hans Goossen; Vinay Gounder; Georgina Crosbie; Sonia Hancock; Stephanie Diaz-Guilas; Paul Mainwaring; Peter Swindle; Derek N J Hart
Journal:  J Immunother       Date:  2015 Feb-Mar       Impact factor: 4.456

7.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

Authors:  Eynav Klechevsky; Rimpei Morita; Maochang Liu; Yanying Cao; Sebastien Coquery; Luann Thompson-Snipes; Francine Briere; Damien Chaussabel; Gerard Zurawski; A Karolina Palucka; Yoram Reiter; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

Review 8.  Designing vaccines based on biology of human dendritic cell subsets.

Authors:  Karolina Palucka; Jacques Banchereau; Ira Mellman
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

9.  Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells.

Authors:  Sophie Paczesny; Jacques Banchereau; Knut M Wittkowski; Giovanna Saracino; Joseph Fay; A Karolina Palucka
Journal:  J Exp Med       Date:  2004-06-01       Impact factor: 14.307

Review 10.  Dendritic cells in cancer immunotherapy clinical trials: are we making progress?

Authors:  Lisa H Butterfield
Journal:  Front Immunol       Date:  2013-12-13       Impact factor: 7.561

View more
  68 in total

1.  Engineering Biomaterials to Direct Innate Immunity.

Authors:  R S Oakes; E Froimchuk; C M Jewell
Journal:  Adv Ther (Weinh)       Date:  2019-02-27

2.  Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.

Authors:  Qian-Ting Wang; Ying Nie; Sheng-Nan Sun; Tao Lin; Ru-Jin Han; Jun Jiang; Zhe Li; Jun-Qi Li; Yun-Peng Xiao; Yu-Ying Fan; Xiao-Hui Yuan; Hui Zhang; Bin-Bin Zhao; Ming Zeng; Shi-You Li; Hua-Xin Liao; Jian Zhang; You-Wen He
Journal:  Cancer Immunol Immunother       Date:  2020-02-20       Impact factor: 6.968

Review 3.  Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence.

Authors:  Michael W Graner
Journal:  Annu Rev Genomics Hum Genet       Date:  2019-04-12       Impact factor: 8.929

4.  Noninvasive Photoacoustic Imaging of Dendritic Cell Stimulated with Tumor Cell-Derived Exosome.

Authors:  Yin Ji Piao; Hoe Suk Kim; Woo Kyung Moon
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

Review 5.  Comparison of DNA and mRNA vaccines against cancer.

Authors:  Zohreh Jahanafrooz; Behzad Baradaran; Jafar Mosafer; Mahmoud Hashemzaei; Tayebeh Rezaei; Ahad Mokhtarzadeh; Michael R Hamblin
Journal:  Drug Discov Today       Date:  2019-12-13       Impact factor: 7.851

6.  Dendritic cells loaded with HeLa-derived exosomes simulate an antitumor immune response.

Authors:  Guoping Ren; Yanhong Wang; Shexia Yuan; Baolian Wang
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

7.  Efficient antigen cross-presentation through coating conventional aluminum adjuvant particles with PEI.

Authors:  Hongyan Ren; Yongbin Mou; Lin Lin; Lixin Wang; Hongming Hu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

8.  Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma.

Authors:  Deena M Maurer; Juraj Adamik; Patricia M Santos; Jian Shi; Michael R Shurin; John M Kirkwood; Walter J Storkus; Lisa H Butterfield
Journal:  Cancer Immunol Res       Date:  2020-10-13       Impact factor: 11.151

9.  Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors.

Authors:  Tae Heung Kang; Yeong-Min Park; Gun-Young Jang; Young Seob Kim; Sung Eun Lee; Ji Won Lee; Hee Dong Han
Journal:  Cancer Immunol Immunother       Date:  2020-10-28       Impact factor: 6.968

Review 10.  Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer.

Authors:  Zachary R Stephen; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2020-11-25       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.